Drug Trial Radar · NCT03713658
A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities
Last checked: Nov 20, 2026Latest source record: Apr 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
34
Actual
Start
Oct 18, 2018
Primary completion
Dec 2, 2019
Study completion Dec 2, 2019
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Oct 22, 2018
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Health services research
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the feasibility of conducting a study of oral risperidone followed by paliperidone palmitate for once monthly (PP1M) and paliperidone palmitate for every 3 months (PP3M) in rwandan healthcare facilities with mental healthcare capabilities.
Conditions
- Schizophrenia
Interventions
Risperidone 3 mgDrug
Participants will receive 3 mg oral risperidone tablets once daily for up to one Week.
Paliperidone Palmitate 50 mg eq.Drug
Participants will receive 50 mg eq. PP1M intramuscular injection for 17 Weeks.
Paliperidone Palmitate 75 mg eq.Drug
Participants will receive 75 mg eq. PP1M intramuscular injection for 17 Weeks.
Paliperidone Palmitate 100 mg eq.Drug
Participants will receive 100 mg eq. PP1M intramuscular injection for 17 Weeks.
Paliperidone Palmitate 150 mg eq.Drug
Participants will receive 150 mg eq. PP1M intramuscular injection for 17 Weeks.
Paliperidone Palmitate 175 mg eq.Drug
Participants will receive 175 mg eq. PP3M intramuscular injection for 24 Weeks.
Paliperidone Palmitate 263 mg eq.Drug
Participants will receive 263 mg eq. PP3M intramuscular injection for 24 Weeks.
Paliperidone Palmitate 350 mg eq.Drug
Participants will receive 350 mg eq. PP3M intramuscular injection for 24 Weeks.
Paliperidone Palmitate 525 mg eq.Drug
Participants will receive 525 mg eq. PP3M intramuscular injection for 24 Weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Successful Completion of Study ProceduresTime frame: Up to Week 46
- Percentage of Participants With Successful Delivery of Risperidone/PP1M/PP3M for the Duration of the StudyTime frame: Up to Week 46
- Percentage of Participants With Successful Administration of Risperidone/PP1M/PP3M Throughout the StudyTime frame: Up to Week 46
- Quality of Life as Assessed by World Health Organization Quality of Life Scale Brief Version (WHO QoL-BREF) Total ScoreTime frame: Up to Week 46
- Clinician Satisfaction as Assessed by Clinician Satisfaction Rating Scale ScoreTime frame: Up to Week 46
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
CARAES Ndera Neuro-Psychiatric Hospital
Kigali, Rwanda
Ruhengeri Referral Hospital, Public Hospital
Musanze District, Rwanda
Kibungo Referral Hospital
Ngoma District, Rwanda
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.